Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Mohs Micrographic Surgery
47%
308-nm Excimer Laser
47%
Scrotal Ulcer
47%
Porphyria Cutanea Tarda
47%
Vitiligo Treatment
47%
Vitiligo
47%
Agminated
47%
Eyelid Carcinoma
47%
Malignant Melanoma
47%
All-trans Retinoic Acid
47%
Highly Active Antiretroviral Therapy (HAART)
47%
Acute Promyelocytic Leukemia
47%
Congenital Melanocytic Nevus
47%
Clinical Evaluation
47%
Perspiration
47%
Microwave Devices
47%
Axillary Hyperhidrosis
47%
Acid Activation
47%
Hepatitis C
47%
10-year Survival
47%
Prognostic Model
47%
Patient Survival
47%
Dysplastic Nevus
47%
Primary Cutaneous Melanoma
47%
Melanoma
30%
Surgical Excision
23%
Active Groups
23%
Responder Rate
23%
Sham
23%
Recurrence Rate
23%
Excision
23%
Sebaceous Carcinoma
23%
Tumor Thickness
23%
Metastatic Rate
23%
Local Recurrence
23%
Fresh Tissue
23%
Phototherapy
23%
Repigmentation
23%
Hyperhidrosis Disease Severity Scale
23%
Atypical Mole Syndrome
20%
HIV Infection
17%
Therapeutic Potential
15%
Large Database
15%
Pigmented Lesions
15%
Patient Outcomes
15%
Cutaneous Side Effects
15%
Chronic Venous Ulceration
15%
Dry Skin
15%
University of Pennsylvania
15%
Excimer Laser
15%
Medicine and Dentistry
Melanoma
100%
Mohs Surgery
55%
Steri-Strip
47%
Hyperhidrosis
47%
Vitiligo
47%
Dermatological Agent
47%
Clinical Trial
47%
Sweating
47%
Prospective Study
47%
Dysplastic Nevus Syndrome
47%
Congenital Melanocytic Nevus
47%
Engineered Tissue
47%
Sebaceous Carcinoma
47%
Prognostic Model
47%
Melanoma Skin Cancer
47%
Neoplasm
31%
Surgical Wound
23%
Recurrence Risk
23%
Wound
23%
Recurrent Disease
23%
Phototherapy
19%
Disease Severity
15%
Survival Rate
15%
Base
15%
Logistic Regression Analysis
15%
Pigmented Lesion
15%
Melanocytic Nevus
14%
Morbidity
13%
Treatment Modality
12%
Xenon
9%
Nevus
9%
Chloride
9%
Metastatic Carcinoma
7%
Target Tissue
7%
Adverse Event
7%
Parotid Lymph Nodes
7%
Pagetoid
7%
Meibomian Gland
7%
Sebaceous Gland
7%
Upper Eyelid
7%
Adnexa
7%
Venous Ulcer
7%
Lower Eyelid
7%
Wound Healing
7%
Epithelization
7%
Therapeutic Modality
7%
Diseases
7%
Life Table
5%